Genewise Bio

Established in 2021 and based in Beijing, China, Genewise Bio is a medical testing services company with a primary focus on molecular testing. The company was incubated by BOE Technology Group, and has developed an integrated R&D and production system for microfluidic chips, diagnostic reagents, and testing equipment. The team at Genewise Bio consists of talents from institutions such as Princeton, Tsinghua, Peking University, and the Chinese Academy of Sciences. The company has received Class III medical device registration certificates and CE certification from the National Medical Products Administration (NMPA) for over 20 products. The company offers a range of POCT molecular diagnostic platforms, including pathogen detection, antimicrobial resistance gene testing, and women's and children's health. Key products include the NAT-3000 fully automatic nucleic acid amplification analyzer and the new coronavirus (2019-nCov) and influenza A/B nucleic acid combined detection kit (fluorescent PCR method). The above products have been approved for marketing and have been installed in a number of tertiary hospitals and children's medical centers in various regions. The company generates revenue by selling its diagnostic products and providing related services, targeting hospitals, medical centers, and laboratories.

1. Series A

   Jun 4, 2024

   Amount

   $14M

   Investors

   Locked